Discover Insights at IMUNON's Upcoming R&D Day
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, is set to host an engaging R&D Day, offering both in-person and virtual attendance options on November 10, 2025, at the Harvard Club in New York City. This exciting event aims to update attendees on the progression of groundbreaking cancer research, particularly focusing on its pivotal Phase 3 study of IMNN-001, a DNA-mediated immunotherapy.
What to Expect from the Event
The R&D Day will feature prominent figures in the field of oncology, including ovarian cancer thought leaders and principal investigators who are pivotal to the ongoing OVATION 3 Study. Attendees can look forward to presentations that delve into recent findings, safety profiles, and statistical insights pertaining to IMNN-001. The event will kick off at 8:00 a.m. ET and will include interactive sessions with opportunities for questions and networking with experts in the field.
Key Presentations and Notable Speakers
The R&D Day promises several notable presentations, such as:
- Title: Advancing Ovarian Cancer Care: IMNN-001’s Potential to Transform the Microtumor Environment from Cold to Hot in Phase 3
Presenter: Dr. Premal H. Thaker, a distinguished professor and chief of gynecologic oncology at Washington University School of Medicine. - Title: Unveiling Progress: Safety, Tolerability, and Translational Insights for IMNN-001
Presenter: Dr. Amir Jazaeri, Vice Chair for Clinical Research at the University of Texas MD Anderson Cancer Center. - Title: OVATION 3 Probability of Success & the Statistical Properties of Phase 3 Trial Design
Presenter: Dr. Giorgio Paulon, Senior Statistical Scientist at Berry Consultants, LLC. - Title: Phase 3 OVATION 3 Trial Update
Presenter: Dr. Douglas V. Faller, Chief Medical Officer at IMUNON.
About IMUNON's Innovative Approaches
IMUNON is making strides in the biotechnology field with its cutting-edge DNA-based therapies designed to tackle cancer more effectively. The company’s lead clinical program, IMNN-001, represents a forefront approach in treating advanced ovarian cancer by mobilizing the body’s immune response to target tumors directly. This DNA-mediated immunotherapy has shown promising results in previous clinical trials, solidifying IMUNON's commitment to revolutionizing cancer treatment.
Besides its focus on ovarian cancer, IMUNON is also exploring applications for its technologies in other challenging conditions, including efforts in COVID-19 vaccine innovations. The potential to leverage such therapies signifies a transformative journey for medicine, as the company remains at the edge of scientific progress.
How to Register
Registration for this informative event is essential. Interested participants can secure their spot, either for in-person attendance or virtually, by RSVP’ing through the provided link.
Frequently Asked Questions
What is the purpose of IMUNON's R&D Day?
The event aims to provide updates on the OVATION 3 Study and showcase advancements in cancer therapies involving IMNN-001.
Who can attend the R&D Day?
Investors, healthcare professionals, and anyone interested in advancements in cancer treatments are welcome to attend.
When is the event taking place?
The R&D Day is scheduled for November 10, 2025, starting at 8:00 a.m. ET.
What should attendees expect from the presentations?
Attendees will gain insights from leading experts in oncology, presenting data on safety, efficacy, and potential future developments regarding IMNN-001.
How can I secure a spot for the event?
Registration can be completed online, with options for both in-person and virtual attendance available for interested individuals.
